KDR and hepatocellular carcinoma: Sorafenib, one of the medications which is FDA approved for advanced HCC, is a systemic oral therapy which inactivates multiple kinase proteins, including vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor receptor (PDGFR) and rapidly accelerated fibrosarcoma (RAF) kinases, halting pathways responsible for angiogenesis and cell growth [46,47].